TORRENT PHARMACEUTICALS LTD. approved audited financial results for the quarter and year ended March 31, 2024, recommended a final dividend, enabling approval for issuing Equity Shares up to Rs 5,000 crores via QIP, approved re-appointment of Samir Mehta as Executive Chairman, and appointed Jinal Mehta as a Non-Executive Director while Jinesh Shah stepped down as Director.